<DOC>
	<DOCNO>NCT00046800</DOCNO>
	<brief_summary>The purpose study estimate efficacy safety OSI-211 topotecan patient relapse epithelial ovarian cancer .</brief_summary>
	<brief_title>Study OSI-211 vs. Topotecan Patients With Relapsed Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lurtotecan</mesh_term>
	<criteria>Confirmed relapse ovarian cancer . Measurable disease great equal 20 mm ( great equal 10 mm spiral CT scan ) . One two prior regimen chemotherapy . At least one regimen must contain cisplatin carboplatin . At least three week since prior chemotherapy recovery related toxicity . At least four week since prior radiotherapy recovery related toxicity .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>